Abstract
Introduction

Alzheimer's disease (AD) is the leading cause of dementia among people aged 65 and older. The disease is characterized by a slow progressive loss of cognition, behavioural changes and loss of independence that ends in the complete destruction of the personality. AD is characterized by the presence in the brain of extracellular neuritic plaques (mainly constituted of aggregated amyloid ␤-peptide [A␤]), and intraneuronal neurofibrillary tangles (NFT) (rich in abnormally phosphorylated tau). The vast majority of AD cases are sporadic and the primary causes of the disease remain elusive. There is a small percentage of familial cases with a clear genetic component due to a mutation in the genes
either for the amyloid precursor protein (APP) or presenilins [1] . (77-78%) in the general population, while apoE2 is found in 7-8% and apoE4 in 14 [2] .
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The strongest known risk factor influencing the incidence of sporadic AD is the genotype for apolipoprotein E (ApoE). ApoE is the major carrier of cholesterol in the CNS. In humans, the apoE gene shows polymorphism, with three different alleles (e2, e3 and e4), that give rise to six different phenotypes (E2/2, E2/3, E2/4, E3/3, E3/4 and E4/4). ApoE3 is the most common isoform
Since the discovery of the apoE4/AD association, abundant experimental studies have shown that apoE influences the majority of the AD pathological processes (A␤ generation or deposition, NFT formation, neuronal survival, lipid homeostasis, intracellular signalling, etc.). In all cases, apoE4 was shown to be detrimental (due to either negative or lack of positive effects) compared with other isoforms. However, due to the omnipresence of apoE in all the biochemical disturbances characteristic of AD, it has been difficult to propose a simple and integrative hypothesis that could explain the mechanisms by which apoE4 increases the susceptibility for this disease.
In addition, it has also been shown that the presence of apoE4 has a large impact on longevity, cardiovascular diseases and different other neurological disorders including stroke, cerebral amyloid angiopathy [3] , Lewy body disease [4] , multiple sclerosis [5] , Parkinson's disease [6] 
ApoE function
The largest production of apoE is found in the liver, followed by the brain. In the brain, apoE is predominantly secreted by astrocytes and microglia [7, 8] , although even neurons have been reported to produce it [9, 10] .
ApoE is a major determinant of the recognition and uptake of lipoproteins though the low density lipoprotein (LDL) receptor, the LDL receptor related protein (LRP), the apoE receptor 2, the very low density lipoprotein (VLDL) receptor and megalin [11] . ApoE plays an important role in the distribution and metabolism of cholesterol and triglycerides within many organs and cell types in the human body [12] . The apoE polymorphism seen in humans is unique and it has been proposed to appear as a result of evolutionary adaptive changes [13, 14] [12] .
The mechanisms that govern apoE synthesis and secretion in brain are not fully understood. Estrogen has been shown to increase apoE mRNA levels in rat brain in vivo and in astrocytes and mixed glia cultures in vitro [15, 16] . ApoE secretion in rat primary astrocytes can also be modulated by neurotransmitter receptors that regulate intracellular cAMP and protein kinase C (PKC) activity [17] . ApoE secretion from human primary astrocytes can be reduced by the combination of interleukin 1 ␣ and ␤ and interferon ␥ [18] . Moreover, apoE levels increase dramatically in response to peripheral nerve injury in a rat model [19] . A moderate injury induced enhancement of apoE levels has been also shown in CNS [20] [24] , but it has also been shown that apoE3 and E2 bind more rapidly to A␤ when associated with lipoproteins [25] . The dosage of apoE was found to be determinant for plaque deposition in a mice overexpressing the mutant human APP V717F [26] [21] and genetic AD cases [29] . Recently, it has been shown that the cognitive impairment seen in human APP transgenic mice depends both on apoE and on amyloid formation [30] . Thirdly, neuronal ApoE receptors may also have several roles in APP trafficking and processing [31] , in A␤ clearance [32] and apoE4 has been found to enhance the synthesis of A␤ by promoting endocytic recycling of APP [33] .
Finally, in vitro data demonstrate that apoE increases the neurotoxicity of A␤ in an isoform-specific manner (E4 > E3) [34, 35] . In addition, a recent study has shown that the impairments in neuroplasticity induced by apoE4 following environmental stimulation in a transgenic mice model are associated with the accumulation of intraneuronal A␤ [36] . These findings suggest the existence of synergistic pathological effects between A␤ and apoE4.
ApoE and neurofibrillary tangles
Abnormal phosphorylation of the tau protein leading to the formation of NFTs is a common feature of AD, and several other neurodegenerative disorders [37] . [38] . Transgenic mice studies have shown increased phosphorylation of tau in mice expressing human apoE4 in neurons, but not in mice expressing apoE4 in astrocytes [39, 40] , indicating a neuron-specific effect of apoE4 on tau phosphorylation. In addition, intraneuronal accumulation of hyperphosphorylated tau has been found in apoE KO mice fed with a high cholesterol diet, suggesting a synergic interaction of dietary cholesterol and lack of apoE function [41] .
It is believed that tau hyperphosphorylation compromises the normal functioning of the neuron leading to its death. The hypothesis that apoE isoforms may differently influence tau pathology derives from in vitro studies, where apoE3 and not apoE4 forms a (SDS)-stable complex with tau. Phosphorylation of tau inhibits its interaction with apoE3 suggesting that apoE3 only binds to non-phosphorylated tau. This further suggests that apoE3 might be able to prevent abnormal tau hyperphosphorylation and destabilization of the neuronal cytoskeleton
It has been proposed that the amino-terminal domain of apoE3 is responsible for binding to tau [38] . Additionally, studies in transgenic mice have shown that carboxyl-terminal-truncated apoE stimulates tau phosphorylation and intracellular NFT-like inclusion formation in [42] . A direct molecular interaction between the apoE (or apoE fragments) and tau molecules would require that both meet in the same cytosolic compartment. The question of how apoE accesses the neuronal cytoskeleton remains puzzling. An alternative mechanism in which apoE isoforms would differentially contribute to tau hyperphosphorylation is the modulation of tau kinases and phosphatases.
ApoE, cholesterol and synaptic repair
The major function of apoE is to re-distribute lipids and participate in cholesterol homeostasis [12] . In cultured neurons, cholesterol uptake is lower when the lipid is bound to ApoE4 compared to ApoE2 and ApoE3 [43] . ApoE4 is less efficient than other forms in promoting cholesterol efflux from both neurons and astrocytes [44] [54] [55] [56] , while the non-amyloidogenic ␣-secretase is associated with the membrane surface, outside raft domains [57] . ␤-secretase activity is increased by cholesterol [58] . In addition, changes in cholesterol levels or distribution within the membrane have been shown to alter the localization of APP and their availability to be cleaved by these secretases [59, 60] . On the other hand, A␤ modulates the synthesis and the distribution of cholesterol in neurons [61] . Moreover, it has been shown that cholesterol reduces the effects of A␤ on calcium signalling and neurotoxicity in several models [34, 62, 63] [69] . [70] . [71] [72] [73] . In contrast, there are no significant differences in muscarinic receptor levels between AD patients with different apoE genotypes [73] . [75] . In this study, human APP/apoE4 mice showed synaptic and cholinergic deficits prior to plaque formation. However, old human APP/apoE4 and human APP/apoE3 mice had similar synaptic and cholinergic deficits, despite their differences in plaque load [75] .
Such data suggest a lack of function of apoE4 in synaptic regeneration, compared with other apoE isoforms. It is likely that this lack of function will also affect synaptic function. Supporting this idea, it has been reported that long-term potentiation (LTP) is reduced in apoE4-transgenic mice compared with wild-type mice and apoE3 mice
ApoE and cholinergic dysfunction
Cholinergic signal transduction is well known to be impaired in AD. ApoE4 carriers with AD show greater deficits than non-carriers in cholinergic activity in the hippocampus and the cortex, as well as a reduction in the total number of cholinergic neurons, and of cholinergic markers, such as choline acetyltransferase activity and nicotinic ACh receptor binding
Variant apoE isoforms have different effects on ACh muscarinic receptor stimulated signalling in vitro. ApoE4 impaired carbachol-stimulated phosphoinositide hydrolysis, whereas apoE3 alone was without effect. In addition, ApoE3, but not E4, could protect against A␤(1-42)-mediated disruption [74]. In a double transgenic mice model, it has recently been reported that modulation of AD-like cholinergic deficits depends on the apoE isoform, the overproduction of A␤, and the age of the animal, but not on plaque deposition
A direct negative influence of apoE4 on cholinergic signalling may participate in the lower effectiveness of cholinergic replacement treatments reported for apoE4-AD patients [73] . [76] [77] [78] . Also, apoE has isoform-specific effects on the activities of PKC [79] , glycogen synthase kinase-3␤ (GSK-3␤) [76] , protein kinase B (Akt) [76] , extracellular signal-regulated kinase 1/2 (ERK) [80, 81] , c-Jun N-terminal kinase 1/2 (JNK) [80] and on the transcriptional activity of the cAMP response element-binding protein (CREB) [81] 
ApoE and signalling
ApoE has been shown to modulate various signalling pathways, some of which are relevant to AD. In several in vitro models, apoE was shown to affect multiple signalling cascades in an isoform-specific manner. ApoE isoforms differentially influence calcium channels causing different increases in free intracellular calcium
ApoE and neurotoxicity
ApoE may also contribute to neurodegenerative processes by being directly toxic to neurons. In this context, lipid-free apoE (E4 > E3) and apoE-derived fragments have been shown to be toxic to neurons in vitro [34, 84, 85] . However, when instead of delipidated apoE, the more physiological apoE-containing lipoproteins were used, this toxicity was avoided [34] . In fact, apoE-containing lipoproteins were shown to promote cell survival and neurite outgrowth also in an isoform-specific manner (E3 > E4) [86, 87] . These data suggest that apoE status or the conformation of apoE-containing lipoproteins might be an important determinant of apoE neurotoxicity.
In vivo studies using transgenic mice that express human apoE3, apoE4 or both, have demonstrated that apoE3/E3 animals were more protected than apoE3/4 against age-induced neurodegeneration and that apoE4/4 showed no protection [88] . This would imply that apoE4 is not only less neuroprotective than apoE3, but also acts as a dominant negative factor interfering with the beneficial function of apoE3.
It has been reported that a N-terminal proteolytic fragment (amino acids ) is responsible for apoE toxicity by increasing intracellular calcium levels [85] . Conversely, several reports from another group have shown that the C-terminal fragment of apoE is neurotoxic in vitro by a mechanism that involves mitochondrial and cytoskeletal alterations [84] . In vivo, apoE4 C-terminal fragments were shown to induce neurodegeneration and behavioural deficits in transgenic mice [42] . Importantly, apoE Cterminal fragments were present at much higher levels in the brains of AD patients (especially associated with NFT) than in controls [40, 89] [95] . Those peptides showed improved outcomes in animal models of multiple sclerosis [96] and brain injury [97] [99] . The use of these molecules would restore the ability of apoE4 for carrying lipids and would reduce the rate of apoE4 cleavage to the levels of apoE3. Theoretically, this strategy would both decrease the negative effects and potentiate the protective effects of apoE4 simultaneously.
Other apoE-based therapeutical strategies have also been proposed. Using an inhibitor of the apoE protease would prevent the generation of the detrimental apoE fragments [84] . Blocking the interaction of apoE4-derived fragments with the mitochondria would prevent the detrimental effects on mitochondrial function [100] . Despite the difficulties, apoE remains as an area of enormous potential for drug development for the treatment of AD and other neurodegenerative disorders.
Conclusions
The presence of apoE4 is the most important known risk factor for AD. ApoE is the only molecule that has been associated with all the biochemical disturbances characteristic of the disease: A␤ deposition, tangle formation, neurodegeneration, lipid dysfunction, loss of synaptic plasticity, cholinergic dysfunction and disruption of signalling (Fig. 1) . The presence of apoE4 exacerbates these disturbances, while other apoE isoforms are protective. Several exciting new apoE-based therapeutic strategies for AD are under research (Fig. 2) 
